Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.48 |
| ▸ | TUBB | P07437 | 2/20 | 0.48 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.48 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.48 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.48 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.48 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.48 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20435859 | 0.89 | CYP1A2 (0.55) | CYP1A2CYP3A4CYP2C9CYP2C19HPGD | |
| SCHEMBL20435870 | 0.87 | HPGD (0.58) | HPGDMAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL20435891 | 0.86 | CYP1A2 (0.58) | CYP1A2CYP3A4CYP2C9CYP2C19HPGD | |
| SCHEMBL20435871 | 0.83 | CYP1A2 (0.58) | CYP1A2CYP3A4CYP2C9CYP2C19HPGD | |
| SCHEMBL20435873 | 0.83 | CYP1A2 (0.55) | CYP1A2CYP3A4CYP2C9CYP2C19HPGD | |
| SCHEMBL20435872 | 0.82 | HPGD (0.55) | CYP1A2CYP3A4CYP2C9CYP2C19HPGD | |
| SCHEMBL20435862 | 0.78 | AKR1B1 (0.58) | HPGDMAPTSMN1; SMN2ADORA3ADORA2B | |
| SCHEMBL28869603 | 0.76 | MAPT (0.61) | CYP1A2CYP3A4CYP2C9CYP2C19HPGD | |
| SCHEMBL1544017 | 0.76 | MAPT (0.65) | CYP1A2CYP3A4CYP2C9CYP2C19MAPT | |
| SCHEMBL20435725 | 0.76 | HPGD (0.58) | CYP3A4CYP2C9HPGDMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377442-B2 | Small molecule agonists and antagonists of NR2F6 activity | Zander Biologics, Inc (US) | 2022-07-05 | — | — | US | disclosed |
| US-11324719-B2 | Small molecule agonists and antagonists of NR2F6 activity in humans | KCL THERAPEUTICS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-20200071307-A1 | SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN ANIMALS | Zander Therapeutics, Inc. (US) | 2020-03-05 | — | — | US | disclosed |
| US-10472351-B2 | Small molecule agonists and antagonists of NR2F6 activity in animals | Zander Therapeutics, Inc. (US) | 2019-11-12 | — | — | US | disclosed |
| WO-2019104201-A1 | SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN NON-HUMANS | Zander Therapeutics, Inc. (US) | 2019-05-31 | — | — | WO | disclosed |
| WO-2019104199-A1 | SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY | REGEN BIOPHARMA INC. (US) | 2019-05-31 | — | — | WO | disclosed |
| US-20190054118-A1 | Small Molecule Agonists and Antagonists of NR2F6 Activity in Animals | Zander Therapeutics, Inc. | 2019-02-21 | — | — | US | disclosed |
| US-20180214413-A1 | Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans | KCL THERAPEUTICS, INC | 2018-08-02 | — | — | US | disclosed |
| US-20180214413-A1 | Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans | KCL THERAPEUTICS, INC | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180214413-A1 | Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans | NR4A2, NR2C2, NR0B2 | CYP1A2 1825/4885CYP3A4 3020/4885CYP2C9 4313/4885 |
| US-20200071307-A1 | SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN ANIMALS | NR4A2, NR2C2, NR0B2 | CYP1A2 2074/4885CYP3A4 3544/4885CYP2C9 4550/4885 |
| US-20190054118-A1 | Small Molecule Agonists and Antagonists of NR2F6 Activity in Animals | NR4A2, NR2C2, NR0B2 | CYP1A2 2074/4885CYP3A4 3544/4885CYP2C9 4550/4885 |
| US-11324719-B2 | Small molecule agonists and antagonists of NR2F6 activity in humans | NR4A2, NR2C2, NR0B2 | CYP1A2 1825/4885CYP3A4 3020/4885CYP2C9 4313/4885 |
| US-11377442-B2 | Small molecule agonists and antagonists of NR2F6 activity | NR4A2, NR2C2, NR2F2 | CYP1A2 2300/4885CYP3A4 3450/4885CYP2C9 4587/4885 |
| US-10472351-B2 | Small molecule agonists and antagonists of NR2F6 activity in animals | NR4A2, NR2C2, NR0B2 | CYP1A2 2074/4885CYP3A4 3544/4885CYP2C9 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.